Comment on the article of E.A. Lebedeva et al. “Basic therapy of traumatic brain injury using catecholamine agonist”

A.A. Belkin


References

  1. Samson A.J., Robertson G., Zagnoni M., Connolly C.N. Neuronal networks provide rapid neuroprotection against spreading toxicity. Sci. Rep. 2016; 6: 33746. doi: 10.1038/srep33746.
  2. Giacino J.T., Whyte J., Bagiella E., et al. Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury. N. Engl. J. Med. 2012; 366(9): 819–826. doi: 10.1056/NEJMoa1102609.
  3. Kalmar K., Childs N., et al. Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury. Rehabilitation. 2012; 366(9): 819–826. doi: 10.1056/NEJMoa110260.
  4. Belkin A.A., Shchegolev A.V., Kondrat’ev A.N., Bubnova I.D. Use of amantadine sulfate (PK-MERZ) during emergence from coma: results of a multicenter study. Anesteziol. Reanimatol. 2008; 2: 70–73. PMID: 18540467.